BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/25/2025 9:15:16 AM | Browse: 48 | Download: 0
Publication Name World Journal of Hepatology
Manuscript ID 110698
Country Japan
Category Gastroenterology & Hepatology
Manuscript Type Case Control Study
Article Title Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease
Manuscript Source Invited Manuscript
All Author List Tatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiruyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takauma Okamura, Naohiro Komatsu, Miruki Yoshino and Hisamitsu Miyaaki
Funding Agency and Grant Number
Corresponding Author Tatsuki Ichikawa, MD, Department of Gastroenterology, Nagasaki Harbor Medical Center, 1-7-1 Sakamoto, Nagasaki 850-8555, Japan. ichikawa@nagasaki-u.ac.jp
Key Words Cytokeratin 18 fragment; Steatosis-associated fibrosis estimator score; Triglyceride; High-density lipoprotein cholesterol; Steatotic liver disease
Core Tip Serum cytokeratin 18 fragment (CK18F) has been developed as a new non-invasive test for risk assessment of steatotic liver disease (SLD). We included 125 patients who were assessed for SLD and had CK18F measured. Steatosis-associated fibrosis estimator (SAFE) score, liver stiffness (LS), and FibroScan-aspartate aminotransferase (FAST) score were compared with CK18F. CK18F was associated with aspartate aminotransferase, alanine aminotransferase, and triglycerides (TG). FAST and SAFE score were associated with high CK18F (> 260 U/L), but not fibrosis-4 and LS. The risk of high CK18F was higher when high TG and low high-density lipoprotein were combined than when each was present alone.
Citation Ichikawa T, Miuma S, Yamashima M, Yamamichi S, Koike M, Nakano Y, Yajima H, Miyazaki O, Ikeda T, Okamura T, Komatsu N, Yoshino M, Miyaaki H. Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease. World J Hepatol 2025; In press
Received
2025-06-13 09:42
Peer-Review Started
2025-06-13 09:42
To Make the First Decision
Return for Revision
2025-06-26 08:07
Revised
2025-07-03 05:17
Second Decision
2025-09-25 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-09-25 09:15
Articles in Press
2025-09-25 09:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com